Breaking News

Financial Report: BMS

April 29, 2014

Eliquis and AZ diabetes deal drive earnings in the quarter

BMS
 
1Q Revenues: $3.8 billion (-1%)

1Q Earnings: $936 million (+54%)

Comments: The company completed the sale of its diabetes business to AstraZeneca, receiving $3.3 billion in closing and milestone payments during the quarter. Sprycel sales were up 19% to $342 million. Yervoy sales grew 18% to $271 million. Orencia sales were up 13% to $363  million, and Baraclude sales grew 11% to 406 million. Sustiva franchise sales were down 18% to $319 million due to generic competition. Global revenues for Eliquis were $106 million in the quarter, up from $22 million in 1Q13. R&D expenses increased 2% to $946 million in the quarter.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks